PE20211049A1 - Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 - Google Patents
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1Info
- Publication number
- PE20211049A1 PE20211049A1 PE2021000074A PE2021000074A PE20211049A1 PE 20211049 A1 PE20211049 A1 PE 20211049A1 PE 2021000074 A PE2021000074 A PE 2021000074A PE 2021000074 A PE2021000074 A PE 2021000074A PE 20211049 A1 PE20211049 A1 PE 20211049A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- nlrp3
- interleukin
- activity
- 1beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula (I), o una sal, solvato, isomero o tautomero del mismo, donde: R1 es i), ii) o iii); R1z es H, D, halogeno, entre otros; R1a, R1b, R1c, R1d, R1e, R1f, R1g y R1h son H, D, halogeno, -CN, entre otros; R2 es alquilo C1-C6, cicloalquilo C3-C10, entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son derivados de sulfonilureas inhibidores de inflamasona (tal como inflamasoma de proteina 3 que contiene un dominio de pirina (NLRP3)), IL-6, IL-1beta, IL-17, entre otros, siendo utiles en el tratamiento de un trastorno sensible a la modulacion de citocinas tales como IL-1beta e IL-18, modulacion de NLRP3 o inhibicion de la activacion de NLRP3 o componentes relacionados del proceso inflamatorio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042703 WO2020018970A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211049A1 true PE20211049A1 (es) | 2021-06-04 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000074A PE20211049A1 (es) | 2018-07-20 | 2019-07-19 | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (es) |
| EP (1) | EP3823726A1 (es) |
| JP (1) | JP7411631B2 (es) |
| KR (1) | KR20210034588A (es) |
| CN (1) | CN112437683A (es) |
| AR (1) | AR117617A1 (es) |
| AU (1) | AU2019305095A1 (es) |
| BR (1) | BR112021001012A2 (es) |
| CA (1) | CA3104199A1 (es) |
| CL (1) | CL2021000152A1 (es) |
| CO (1) | CO2021000817A2 (es) |
| CR (1) | CR20210024A (es) |
| IL (1) | IL280139A (es) |
| MA (1) | MA53170A (es) |
| MX (1) | MX2021000660A (es) |
| PE (1) | PE20211049A1 (es) |
| PH (1) | PH12020552155A1 (es) |
| SG (1) | SG11202012159TA (es) |
| TW (1) | TW202019937A (es) |
| WO (1) | WO2020018970A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3851434A1 (en) | 2017-01-23 | 2021-07-21 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| BR112020003014A2 (pt) | 2017-08-15 | 2020-07-28 | Inflazome Limited | sulfonilureias e sulfoniltioureias como inibidores de vnlrp3 |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| MY209754A (en) | 2019-11-12 | 2025-07-31 | Kangbaida Sichuan Biotechnology Co Ltd | Amide derivative and preparation method therefore and use thereof in medicine |
| WO2021255279A1 (en) | 2020-06-19 | 2021-12-23 | Ac Immune Sa | D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway |
| US20250109126A1 (en) | 2021-12-22 | 2025-04-03 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2023158824A1 (en) * | 2022-02-21 | 2023-08-24 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity |
| AU2023307538A1 (en) | 2022-07-14 | 2025-01-23 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| PT964849E (pt) * | 1997-01-29 | 2003-08-29 | Pfizer | Derivados de sulfonilureia e sua utilizacao no controlo da actovidade da interleucina-1 |
| WO2001019390A1 (en) | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| AU2002341321A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| US9457084B2 (en) * | 2010-02-22 | 2016-10-04 | Raqualia Pharma Inc. | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases |
| US20140221340A1 (en) | 2011-09-02 | 2014-08-07 | Kyowa Hakko Kirin Co., Ltd. | Chemokine receptor activity regulator |
| PT3259253T (pt) * | 2015-02-16 | 2020-03-11 | Univ Queensland | Sulfonilureias e compostos relacionados e uso dos mesmos |
| BR112018016671A2 (pt) * | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| WO2017184623A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| MA44734A (fr) | 2016-04-18 | 2021-05-19 | Novartis Ag | Composés et compositions destinés au traitement d'états associés à une activité de nlrp |
| EP3851434A1 (en) | 2017-01-23 | 2021-07-21 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| JP7072586B2 (ja) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
| WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| HUE057414T2 (hu) | 2017-07-07 | 2022-05-28 | Inflazome Ltd | Új szulfonamid karboxamid vegyületek |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019034688A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| MA49901A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| BR112020003014A2 (pt) | 2017-08-15 | 2020-07-28 | Inflazome Limited | sulfonilureias e sulfoniltioureias como inibidores de vnlrp3 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| CA3103664A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
| CN112584899A (zh) | 2018-07-03 | 2021-03-30 | 诺华股份有限公司 | Nlrp调节剂 |
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| TWI811400B (zh) | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | 經進一步取代之三唑并喹噁啉衍生物 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| MX2021001754A (es) | 2018-08-15 | 2021-04-19 | Inflazome Ltd | Compuestos de sulfonamidaurea novedosos. |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020154321A1 (en) | 2019-01-22 | 2020-07-30 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
-
2019
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/pt not_active Application Discontinuation
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/es unknown
- 2019-07-19 CR CR20210024A patent/CR20210024A/es unknown
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/ja active Active
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/en not_active Ceased
- 2019-07-19 CA CA3104199A patent/CA3104199A1/en active Pending
- 2019-07-19 MA MA053170A patent/MA53170A/fr unknown
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/ko not_active Withdrawn
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/en active Pending
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/es unknown
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/zh active Pending
- 2019-07-22 TW TW108125890A patent/TW202019937A/zh unknown
- 2019-07-22 AR ARP190102054A patent/AR117617A1/es not_active Application Discontinuation
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/es unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7411631B2 (ja) | 2024-01-11 |
| WO2020018970A1 (en) | 2020-01-23 |
| CL2021000152A1 (es) | 2021-07-09 |
| SG11202012159TA (en) | 2021-01-28 |
| IL280139A (en) | 2021-03-01 |
| CA3104199A1 (en) | 2020-01-23 |
| TW202019937A (zh) | 2020-06-01 |
| KR20210034588A (ko) | 2021-03-30 |
| US11560391B2 (en) | 2023-01-24 |
| CN112437683A (zh) | 2021-03-02 |
| MA53170A (fr) | 2021-05-26 |
| PH12020552155A1 (en) | 2021-07-05 |
| US20210261568A1 (en) | 2021-08-26 |
| BR112021001012A2 (pt) | 2021-04-20 |
| JP2021530536A (ja) | 2021-11-11 |
| CO2021000817A2 (es) | 2021-02-17 |
| AR117617A1 (es) | 2021-08-18 |
| CR20210024A (es) | 2021-02-22 |
| EP3823726A1 (en) | 2021-05-26 |
| MX2021000660A (es) | 2021-03-25 |
| AU2019305095A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211049A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| CL2019001988A1 (es) | Compuestos químicos como inhibidores de actividad interleuquina-2. | |
| MA53388A (fr) | Inhibiteurs d'inflammasome nlrp3 | |
| CO2020010465A2 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| PE20210003A1 (es) | Compuestos de purinona y su uso en el tratamiento del cancer | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| PE20081262A1 (es) | Derivados de fenilo como moduladores de cinasas y composiciones | |
| PE20061367A1 (es) | Nuevos derivados del fluoreno y composiciones que los contienen | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| CO2019011877A2 (es) | Nuevos derivados de pirazol bicíclicos | |
| UY32859A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| CO2020013876A2 (es) | Nuevos derivados de quinolina | |
| PE20200932A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| PE20210176A1 (es) | Inhibidores de arginasa y sus metodos de uso | |
| CL2021003568A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198) | |
| CO2021010689A2 (es) | Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo | |
| AR094735A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4 | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| ECSP21013743A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| MX2018003930A (es) | Inhibidores de calicreína plasmática humana. | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| DOP2018000075A (es) | Compuestos trifluoroalquenilo heterocíclicos con actividad nematicida, sus composiciones agronómicas y el uso de las mismas |